Dr. Scott Rowlinson

Dr. Scott Rowlinson is a seasoned executive with more than 25 years of experience in the biotechnology sector, specializing in biologics drug discovery and clinical development. His expertise spans rare diseases and oncology, where he has demonstrated remarkable leadership as a senior research and development executive.

In his early career at Eli Lilly and Company, Dr. Rowlinson focused on antibody target discovery, leading teams to successful IND submissions and advancing therapies in immuno-oncology and kidney disease. As a pivotal member of the executive team at Aeglea Biotherapeutics, he played an instrumental role in the company’s journey from inception in 2013 through its IPO in 2016, helping progress multiple molecules into the clinic in the areas of oncology and rare disease.  The most advanced of these has been approved by the EMA and is under review by the FDA. Most recently, Dr. Rowlinson served as Chief Scientific Officer at Beyond Cancer, overseeing the development of an innovative gas delivery therapeutic approach. His combined responsibilities have included pipeline discovery and build, corporate research strategy, intellectual property development, regulatory submissions, and investor relations, showcasing his ability to align scientific pursuits with business objectives.

Dr. Rowlinson’s Six Sigma Black Belt training enhances his operational efficiency, and his strong communication and leadership skills have fostered the development of high-performing teams across functional areas. His commitment to forward-thinking, disciplined leadership makes him an asset to driving innovation at Phoreus Biotech.